Séverine Vermeire

University Hospitals Leuven

Belgium

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

30%

Clinical Nutrition

40%

Inflammatory Bowel Disease

50%

Inflammatory Disease

40%

Inflammatory Biology

30%

Graft-versus-host Disease

30%

Patient-reported Outcome

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease

Article Link

Year:

2023

Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension

Article Link

Year:

2023

Baseline <i>TREM-1</i> Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn’s Disease in the SERENE Studies

Article Link

Year:

2023

Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE

Article Link

Year:

2023

Venous Thromboembolism in psoriasis patients: a retrospective monocentric chart review on an overlooked comorbidity

Article Link

Year:

2023

Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies

Article Link

Year:

2023

Microbiome variance of the small bowel in Crohn’s disease

Article Link

Year:

2023

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

Article Link

Year:

2023

Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial

Article Link

Year:

2023

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

Article Link

Year:

2023

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study

Article Link

Year:

2023

Collaborators8

Mamoru Watanabe

JAPAN

Tom Hillary

BELGIUM

Remo Panaccione

Director, Inflammatory Bowel disease Unit, Professor of Medicine

University of Calgary

CANADA

Subrata Ghosh

University of Birmingham

UNITED KINGDOM

Lucas Wauters

BELGIUM

Debby Thomas

Katholieke Universiteit Leuven

BELGIUM

Bram Verstockt

Assistant professor

KU Leuven

BELGIUM

David Rubin

Professor

University of Chicago

UNITED STATES

How do I reach out?

Meet Kite AI